
Shares of Nektar Therapeutics (NASDAQ:NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.
The Nektar Therapeutics Analyst: Greg Harrison reiterated an Underperform rating for Nektar Therapeutics while reducing the price target from $6 to $5.